Drugmakers Pfizer and BioNTech have said that their Covid-19 vaccine remained 100 per cent effective in children aged 12 to 15 years, four months after the second dose.
The companies said that the new data will help support their applications for full approval in the United States and worldwide.
Also watch: Israel starts Covid vaccines for kids aged 5 to 11 amid 'children wave' fears
The new study analysed 2,228 trial participants, the vaccine makers said.
According to an AFP report, no serious safety concerns were observed in individuals with at least six months of follow-up after the second dose.
The vaccine was granted "emergency use authorization" for adolescents by the US in May and the companies plan to soon seek full approval. The vaccine is currently only fully approved in people aged 16 and older.